In another action, the HOD called for identifying best practices and enhancing access to high quality, evidence-based treatment of opioid use disorder.
Specifically, delegates called for:
- The AMA Opioid Task Force to work with the American Hospital Association and other relevant organizations to identify best practices being used by hospitals and others to treat opioid-use disorder as a chronic disease—including identifying patients with this condition.
- Initiating or providing opioid agonist or partial agonist therapy in inpatient, obstetric and emergency department settings.
- Providing cognitive and behavioral therapy as well as other counseling as appropriate.
- Establishing appropriate discharge plans—including education about opioid-use disorder.
- Participating in communitywide systems of care for patients and families affected by this chronic medical disease.
- Additionally, delegates directed the AMA to advocate that states evaluate current programs or those that have received federal or state funding to assist physicians, hospitals and their communities to coordinate care for patients the chronic disease of opioid-use disorder.
The AMA also was directed to seek clarification of DEA regulations concerning prescribing buprenorphine in the inpatient setting as well as filling a prescription for buprenorphine from a hospital inpatient pharmacy.
In separate action, the HOD called on the AMA to support legislative and other appropriate efforts to expand and improve pregnant women’s access to evidence-based treatment for substance-use disorders.
In its report, the reference committee noted delegates’ strong support that pregnant women should not be penalized for having a medical disease.
There was further testimony that the AMA does not condone criminal activity or drug use during pregnancy, but that “the focus on treatment for substance-use disorders must remain squarely in the medical realm, with a clear focus on supporting treatment based on the best medical evidence.”
Read more news coverage from the 2018 AMA Annual Meeting.